Last reviewed · How we verify
Pneumoccocal Vaccine
Pneumococcal vaccine stimulates the immune system to produce antibodies against Streptococcus pneumoniae bacteria, preventing infection and disease.
Pneumococcal vaccine stimulates the immune system to produce antibodies against Streptococcus pneumoniae bacteria, preventing infection and disease. Used for Prevention of pneumococcal disease (bacteremia, meningitis, pneumonia) in adults and children.
At a glance
| Generic name | Pneumoccocal Vaccine |
|---|---|
| Also known as | Prevnar 13® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains antigens derived from pneumococcal polysaccharide capsules or conjugated to carrier proteins. These antigens trigger both humoral and cellular immune responses, enabling the body to recognize and neutralize pneumococcal pathogens before they cause invasive disease. Multiple serotypes are included to provide broad protection against common disease-causing strains.
Approved indications
- Prevention of pneumococcal disease (bacteremia, meningitis, pneumonia) in adults and children
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or fatigue
- Headache
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease (PHASE3)
- Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumoccocal Vaccine CI brief — competitive landscape report
- Pneumoccocal Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI